The extract mangosteen plant (Garcinia mangostana Lynn), with antibacterial capacity, was selected for its In vitro effect against frequent enterobacteria in the gastrointestinal tract (GIT) of living beings. In this work, the In vitro antibacterial activity was observed for enterobacteria and other selected ones (Escherichea coli, Staphylococcos aureus, Streptococcus spp., and Klebsiella pneumoniae).The value of the minimum inhibitory concentration (MIC) of the mangosteen extract, the supernatant, precipitate and dehydrated precipitate, commercial product XanGo®, xanthone 9-xanthene® and nanocellulose from Acacia farnesiana and the mixture between these phytobiotic compounds varied between 25 at 100% dilution and 5 to 10 mg/mL respectively. The results showed that there was a significant difference in the bacterial inhibition halos for enterobacteria (P < 0.05); The highest value (mm) was in XanGo® (20 ± 0.6), followed by mangosteen extract (16 ± 1.1), xanthone 9-xanthene® (7 ± 0.7) and nanocellulose (1 ± 0.1). For the Staphylococcus aureus group, the highest value recorded (mm) was XanGo® (20.13 ± 0.94), followed by mangosteen extract (16 ± 0.88), xanthone 9-xanthene® (7 ± 0.58) and nanocellulose (1 ± 0.33), so there are significant differences in the mixture between the phytobiotic compounds, where the highest achievement of inhibition was observed (11.3 ± 1.30), in the mixture of mangosteen extract and nanocellulose (1:1 dilution), with activity against Staphylococcus aureus strain 448. In the mixture of phytobiotic compounds, the highest achievement of inhibition for enterobacteria was observed (10.3 ± 0.2), with xanthone 9-xantene® and nanocellulose (1:1 dilution), for which is concluded in this study, the In vitro antibacterial activity of XanGo®, the mangosteen extract and xanthone 9-xanthene® is effective against enterobacteria, common pathogens of the digestive tract..